• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM.预测可切除非小细胞肺癌患者的生存率：超越TNM分期。
J Thorac Dis. 2012 Apr 1;4(2):214-6. doi: 10.3978/j.issn.2072-1439.2012.03.06.
2
[Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].[PET/CT最大标准摄取值在可切除肺鳞状细胞癌预后中的作用分析及其与临床病理特征的相关性]
Zhongguo Fei Ai Za Zhi. 2016 Apr 20;19(4):192-9. doi: 10.3779/j.issn.1009-3419.2016.04.03.
3
Evaluating the Potential of T Cell Receptor Repertoires in Predicting the Prognosis of Resectable Non-Small Cell Lung Cancers.评估T细胞受体库在预测可切除非小细胞肺癌预后中的潜力
Mol Ther Methods Clin Dev. 2020 May 22;18:73-83. doi: 10.1016/j.omtm.2020.05.020. eCollection 2020 Sep 11.
4
Predicting Lung Cancer Survival Using Probabilistic Reclassification of TNM Editions With a Bayesian Network.使用贝叶斯网络对 TNM 分期进行概率重新分类预测肺癌生存。
JCO Clin Cancer Inform. 2020 May;4:436-443. doi: 10.1200/CCI.19.00136.
5
Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non-small-cell Lung Cancer.2043 例手术治疗非小细胞肺癌患者第八版肺癌 TNM 分期系统的验证。
Clin Lung Cancer. 2017 Nov;18(6):e457-e466. doi: 10.1016/j.cllc.2017.04.001. Epub 2017 Apr 12.
6
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).诱导化疗和同期放化疗后可切除 IIIA(N2)和部分 IIIB 期非小细胞肺癌患者的手术与根治性同期放化疗增敏的 III 期研究（ESPATUE）
J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.
7
Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China.基于中国多中心研究的 4 个长链非编码 RNA 标志物预测非小细胞肺癌患者预后的分析。
J Transl Med. 2020 Aug 20;18(1):320. doi: 10.1186/s12967-020-02485-8.
8
[Comparison of clinical and surgico-pathological TNM stage of 2007 lung cancer patients].[2007年肺癌患者临床与外科病理TNM分期的比较]
Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):551-3.
9
A new PET/CT volumetric prognostic index for non-small cell lung cancer.一种用于非小细胞肺癌的新型PET/CT体积预后指数。
Lung Cancer. 2015 Jul;89(1):43-9. doi: 10.1016/j.lungcan.2015.03.023. Epub 2015 Apr 9.
10
Lung Cancer Staging and Prognosis.肺癌分期与预后
Cancer Treat Res. 2016;170:47-75. doi: 10.1007/978-3-319-40389-2_3.

引用本文的文献

1
Two Interventions on Pathologic Nodal Staging in a Population-Based Lung Cancer Resection Cohort.两种干预措施对基于人群的肺癌切除队列中病理性淋巴结分期的影响。
Ann Thorac Surg. 2024 Mar;117(3):576-584. doi: 10.1016/j.athoracsur.2023.08.026. Epub 2023 Sep 5.
2
The number of resected lymph nodes is associated with the long-term survival outcome in patients with T2 N0 non-small cell lung cancer.在T2 N0非小细胞肺癌患者中，切除的淋巴结数量与长期生存结果相关。
Cancer Manag Res. 2018 Dec 12;10:6869-6877. doi: 10.2147/CMAR.S186047. eCollection 2018.
3
Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma.甲状腺转录因子-1表达在晚期肺腺癌患者中的预后价值
In Vivo. 2018 Nov-Dec;32(6):1571-1579. doi: 10.21873/invivo.11416.
4
Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.具有治愈意图的非小细胞肺癌切除术后病理淋巴结分期质量与生存的相关性研究。
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.
5
Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis.B7-H4在非小细胞肺癌患者中的预后作用：一项荟萃分析。
Oncotarget. 2017 Apr 18;8(16):27137-27144. doi: 10.18632/oncotarget.15648.
6
Improving post-resection risk stratification in non-small cell lung cancer: 'wit, whither wander you?'.改善非小细胞肺癌切除术后的风险分层：“智慧啊，你要飘向何方？”
J Thorac Dis. 2016 Sep;8(9):2315-2318. doi: 10.21037/jtd.2016.08.54.
7
Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes.基于转移淋巴结数量和比例对非小细胞肺癌（NSCLC）中N描述符新分类的评估。
J Cardiothorac Surg. 2016 Apr 14;11(1):68. doi: 10.1186/s13019-016-0456-5.
8
Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.程序性细胞死亡配体1表达在非小细胞肺癌患者中的预后价值：来自一项更新的荟萃分析的证据
Onco Targets Ther. 2015 Dec 1;8:3595-601. doi: 10.2147/OTT.S91469. eCollection 2015.
9
A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System.美国军事医疗体系中非小细胞肺癌患者死亡率预测预后模型。
J Thorac Oncol. 2015 Dec;10(12):1694-702. doi: 10.1097/JTO.0000000000000691.
10
Improving the pathologic evaluation of lung cancer resection specimens.提高肺癌切除标本的病理评估。
Transl Lung Cancer Res. 2015 Aug;4(4):432-7. doi: 10.3978/j.issn.2218-6751.2015.07.07.

本文引用的文献

1
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.一种实用的分子检测方法，可预测非小细胞肺癌（非鳞癌）切除术后的生存情况：开发和国际验证研究。
Lancet. 2012 Mar 3;379(9818):823-32. doi: 10.1016/S0140-6736(11)61941-7. Epub 2012 Jan 27.
2
Objective review of mediastinal lymph node examination in a lung cancer resection cohort.肺癌切除术患者纵隔淋巴结检查的客观评价。
J Thorac Oncol. 2012 Feb;7(2):390-6. doi: 10.1097/JTO.0b013e31823e5e2d.
3
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.淋巴结隐匿性转移可预测可切除性非小细胞肺癌患者的生存：ACOSOG Z0040 试验报告。
J Clin Oncol. 2011 Nov 10;29(32):4313-9. doi: 10.1200/JCO.2011.35.2500. Epub 2011 Oct 11.
4
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
5
The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer.淋巴结转移数目作为 N1 期非小细胞肺癌患者的预后因素。
Chest. 2011 Aug;140(2):433-440. doi: 10.1378/chest.10-2885. Epub 2011 Feb 3.
6
Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification?对于切除的非小细胞肺癌，哪个是更好的预后因素：转移淋巴结的数量还是目前使用的淋巴结分期分类？
J Thorac Oncol. 2011 Feb;6(2):310-8. doi: 10.1097/JTO.0b013e3181ff9b45.
7
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
8
Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial.纵隔淋巴结清扫术所采集的淋巴结数量：美国外科医师学院肿瘤学组 Z0030 随机、前瞻性试验的结果。
Chest. 2011 May;139(5):1124-1129. doi: 10.1378/chest.10-0859. Epub 2010 Sep 9.
9
Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area.美国大都市地区非小细胞肺癌的手术切除质量。
Cancer. 2011 Jan 1;117(1):134-42. doi: 10.1002/cncr.25334. Epub 2010 Aug 24.
10
Gene expression-based prognostic signatures in lung cancer: ready for clinical use?基于基因表达的肺癌预后标志物：是否准备好用于临床？
J Natl Cancer Inst. 2010 Apr 7;102(7):464-74. doi: 10.1093/jnci/djq025. Epub 2010 Mar 16.

Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM.

作者信息

Osarogiagbon Raymond U

机构信息

Multidisciplinary Thoracic Oncology Program, Baptist Centers for Cancer Care, Memphis, TN, USA.

出版信息

J Thorac Dis. 2012 Apr 1;4(2):214-6. doi: 10.3978/j.issn.2072-1439.2012.03.06.

DOI:10.3978/j.issn.2072-1439.2012.03.06
PMID:22833830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3378237/
Abstract
摘要